Zafgen (Zafgen) Land And Improvements : $0.00 Mil (As of Mar. 2020)

View and export this data going back to 2014. Start your Free Trial

What is Zafgen Land And Improvements?

Zafgen's land and improvements for the quarter that ended in Mar. 2020 was $0.00 Mil.

Zafgen Land And Improvements Historical Data

The historical data trend for Zafgen's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zafgen Land And Improvements Chart

Zafgen Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Land And Improvements

Get a 7-Day Free Trial

Zafgen Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Zafgen Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Zafgen (Zafgen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zafgen Inc (NAS:ZFGN) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Center Plaza, Suite 610, Boston, MA, USA, 02108

Website

http://www.zafgen.com

Zafgen Inc is a US-based biopharmaceutical company. It focuses on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. The lead product candidate of the company is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection. The company operates in the business of developing novel therapeutics. The company primarily carries its business operations in the United States.